These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1321 related items for PubMed ID: 11396237

  • 1. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [Abstract] [Full Text] [Related]

  • 3. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [Abstract] [Full Text] [Related]

  • 4. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W.
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Burris HA, Morrissey LH, Thomas M, Erland JB, Butts JA, Joseph G, Kalman L, Greco FA.
    Cancer J; 2000 Aug; 6(3):151-6. PubMed ID: 10882330
    [Abstract] [Full Text] [Related]

  • 6. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
    Natale RB.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):34-7. PubMed ID: 8643968
    [Abstract] [Full Text] [Related]

  • 7. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH, Paul DM, Hande KR, DeVore R.
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP, Leonardo JM, Karlsson U, Vos P, Bullock L, Thomas P, Lepera P, Ludin A, Chu C, Salehpour M, Jendrasiak G, Sallah S.
    Anticancer Res; 2002 Dec; 22(6B):3429-35. PubMed ID: 12552935
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [Abstract] [Full Text] [Related]

  • 10. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
    Natale RB.
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):2-6. PubMed ID: 8941402
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ, Leighton J, McAleer C, Comis R, O'Dwyer P, Ozols R.
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [Abstract] [Full Text] [Related]

  • 12. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.
    Cancer; 1996 Oct 15; 78(8):1701-7. PubMed ID: 8859183
    [Abstract] [Full Text] [Related]

  • 13. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA.
    Clin Cancer Res; 1997 Jul 15; 3(7):1117-23. PubMed ID: 9815791
    [Abstract] [Full Text] [Related]

  • 14. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA, Garfield DH, Khan MM, Look RM, Boehm KA, Asmar L.
    Lung Cancer; 2005 Jan 15; 47(1):111-20. PubMed ID: 15603861
    [Abstract] [Full Text] [Related]

  • 15. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
    Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pellicciotta M, Ceribelli A, De Marco S, Facciolo F, Cognetti F.
    J Exp Clin Cancer Res; 2004 Mar 15; 23(1):25-32. PubMed ID: 15149147
    [Abstract] [Full Text] [Related]

  • 16. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
    Belani CP, Aisner J, Hiponia D, Engstrom C.
    Semin Oncol; 1995 Aug 15; 22(4 Suppl 9):7-12. PubMed ID: 7544028
    [Abstract] [Full Text] [Related]

  • 17. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 18. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
    Giaccone G, Huizing M, Postmus PE, ten Bokkel Huinink WW, Koolen M, van Zandwijk N, Vermorken JB, Beijnen JH, Dalesio O, Pinedo HM.
    Semin Oncol; 1995 Aug 15; 22(4 Suppl 9):78-82. PubMed ID: 7544030
    [Abstract] [Full Text] [Related]

  • 19. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G.
    Clin Cancer Res; 2008 Mar 01; 14(5):1464-9. PubMed ID: 18316570
    [Abstract] [Full Text] [Related]

  • 20. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 67.